Table 5.
Ongoing clinical trials investigating cancer neo-antigen vaccines.
| Ongoing clinical trials investigating cancer neo-antigen vaccines Study | Cancer Type | Phase | Neo Antigen | Modality | Co-treatment | Status |
|---|---|---|---|---|---|---|
| NCT03639714 | Solid tumors | I/II | GRT-C901/2 | NN | Nivolumab/ipilimumab | Recruiting |
| NCT04864379 | Solid tumors | I | iNeo-Vac-P01 | NN | Anti-PD-1 | Recruiting |
| NCT04072900 | Melanoma | I | rhGM-CSF | NN | Anti-PD-1 | Recruiting |
| NCT02287428 | Glioblastoma | I | Personalized NeoAntigen Vaccine | NN | Pembrolizumab/ Temozolomide/Radiation Tehrapy | Recruiting |
| NCT03361852 | Follicular Lymphoma | I | Neo Vax | s.c. | Rituximab | Not yet recruiting |
| NCT03219450 | Lymphocytic Leukemia | I | NeoVax | s.c. | Pembrolimuzab/Cyclophosphamide | Not yet recruiting |
| NCT02950766 | Kidney Cancer | I | NeoVax | s.c. | Ipilimumab | Recruiting |
| NCT04810910 | Resectable Pancreatic Cancer | I | iNeo-Vac-P01/ GM-CSF | NN | NA | Not yet recruiting |
| NCT04024878 | Ovarian Cancer | I | NeoVax | s.c. | Nivolumab | Recruiting |
| NCT03953235 | Solid tumors | I/II | GRT-C903/4 | NN | Nivolumab/ipilimumab | Recruiting |
| NCT03807102 | Lung Cancer | I/II | Neoantigen Tumor Vaccine | NN | NA | Recruiting |
| NCT04087252 | Solid tumors | I | Tumor neoantigen | i.m. | NA | Recruiting |
| NCT03359239 | Urothelial/Bladder Cancer, NOS | I | Multipeptide Personalized Neoantigen Vaccine (PGV001, ICLC) | NN | Atezolizumab | Recruiting |
| NCT04749641 | Diffuse Intrinsic Pontine Glioma | I | Histone H3.3-K27M Neoantigen Vaccine Therapy | s.c. | NA | Recruiting |
| NCT04799431 | mPCmCRC | I | Neoantigen Vaccine with Poly-ICLC adjuvant | s.c. | Retifanlimab | Not yet recruiting |
| NCT04912765 | Solid Tumors | II | Neoantigen Dendritic Cell Vaccine | i.d.. | Nivolumab | Recruiting |
| NCT04397926 | NSCLC | I | Individualized neoantigen peptides vaccine | s.c. | NA | Recruiting |
| NCT04487093 | NSCLC | I | neoantigen vaccine | s.c. |
|
Recruiting |
| NCT03122106 | Pancreatic cancer | I | Personalized neoantigen DNA vaccine | NN | NA | Active, not recruiting |
| NCT03956056 | Pancreatic cancer | Neoantigen Peptide Vaccine, Poly ICLC | s.c. | NA | Recruiting | |
| NCT03199040 | TNBC | Neoantigen DNA vaccine, TDS-IM system (Inchor Medical Systems) | NN | Durvalumab | Recruiting | |
| NCT03655756 | Melanoma Stage III/IV | I | IFx-Hu2.0 | s.c. | NA | Active, not recruiting |
| NCT04397003 | Extensive-stage SCLC | II | Neoantigen DNA vaccine | NN | Durvalumab | Not yet recruiting |
| NCT02129075 | Cutaneous, Mucosal and Ocular Melanoma | II | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Neoantigen-based Melanoma-Poly-ICLC Vaccine | s.c. | NA | Active, not recruiting |
| NCT04266730 | Squamous NSCLC SCC of Head and Neck |
I | PANDA-VAC | s.c. | Pembrolizumab | Not yet recruiting |
| NCT03558945 | Pancreatic Tumor | I | Personalized neoantigen vaccine | s.c. | NA | Recruiting |
| NCT03468244 | Solid tumors, lymphoma | NN | Naked mRNA | s.c. | NA | Recruiting |
| NCT03815058 | Metastatic melanoma | II | LNP | i.v. | Pembrolizumab | Recruiting |
| NCT03897881 | High-risk melanoma | II | NN | NN | Pembrolizumab | Recruiting |
| NCT03908671 | Esophageal cancer, NSCLC | NN | LNP | s.c. | NA | Not yet Recr4 times uiting |
| NCT04161755 | Pancreas cancer | I | NN | NN | Atezolizumab, chemotherapy | Recruiting |
Abbreviations:i.d., intradermal; i.m., intramuscular; i.n., intranodal; i.v., intravenous; s.c., subcutaneous; NN, not known, NSCL, non-small cell lung cancer; SCC, squamous cell cancer; TAA, tumor-associated antigen; TNBC, triple negative breast cancer; LNP, lipid nanoparticle; NA, not applicable; mCRC, metastatic colorectal cancer; mPC, metastatic pancreatic cancer; TNBC, triple negative breast cancer, SCLC, small cell lung cancer.